HeXun Biosciences (6986) reported revenue of NT$10.6 million for Oct 2026, -59.8% year on year and -36.4% from the previous month. Revenue for Jan–Oct 2026 was NT$230.5 million (-1.7% year on year).
In Oct 2026, it ranked No. 135 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$10.6 million | -59.8% | -36.4% |
| Sep 2026 | NT$16.7 million | -22.7% | -21.8% |
| Aug 2026 | NT$21.4 million | +4.8% | +39.9% |
| Jul 2026 | NT$15.3 million | +5.8% | -49.6% |
| Jun 2026 | NT$30.4 million | +13.4% | -35.1% |
| May 2026 | NT$46.8 million | +10.1% | +180.0% |
| Apr 2026 | NT$16.7 million | -46.8% | -56.1% |
| Mar 2026 | NT$38.1 million | +80.8% | +99.6% |
| Feb 2026 | NT$19.1 million | +10.9% | +24.3% |
| Jan 2026 | NT$15.4 million | +23.1% | -54.6% |
| Dec 2025 | NT$33.8 million | +5.4% | +35.1% |
| Nov 2025 | NT$25 million | -7.3% | -5.5% |
| Oct 2025 | NT$26.5 million | +0.3% | +22.1% |
| Sep 2025 | NT$21.7 million | +1.8% | +6.0% |
| Aug 2025 | NT$20.4 million | -27.3% | +41.2% |
| Jul 2025 | NT$14.5 million | -30.7% | -46.0% |
| Jun 2025 | NT$26.8 million | -52.1% | -37.0% |
| May 2025 | NT$42.5 million | +7.4% | +35.4% |
| Apr 2025 | NT$31.4 million | +72.3% | +49.0% |
| Mar 2025 | NT$21.1 million | +210.2% | +22.4% |
| Feb 2025 | NT$17.2 million | +628.0% | +38.1% |
| Jan 2025 | NT$12.5 million | +19.8% | -61.1% |
| Dec 2024 | NT$32.1 million | -18.1% | +18.9% |
| Nov 2024 | NT$27 million | +34.9% | +2.3% |
| Oct 2024 | NT$26.4 million | +129.5% | +23.9% |
Jan–Oct 2026 cumulative: NT$230.5 million (-1.7% YoY)
Other Biotech & Medical companies
Compare with peers: HeXun Biosciences vs PEC / HeXun Biosciences vs Lotus Pharm / HeXun Biosciences vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
因10月份工作日天數較少,使特定專案執行時程遞延,導致收入認列較去年同期減少
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16